Ertugliflozin: Promise From Yet Another SGLT-2 Inhibitor (CME/CE)

(MedPage Today) -- Assessed as triple agent therapy when added to metformin, sitagliptin
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news